Diurnal Group PLC Presentation at European Congress of Endocrinology

TIDMDNL

Diurnal Group PLC

23 May 2022

23 May 2022

Diurnal Group plc

("Diurnal" or the "Company")

Diurnal to present research into the treatment of congenital adrenal hyperplasia at 24(th) European Congress of Endocrinology meeting

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, will be presenting research findings on the treatment and management of congenital adrenal hyperplasia (CAH) at this year ' s European Congress of Endocrinology, which takes place 21-24 May 2022 in Milan, Italy.

Over the four-day meeting, the following topics will be presented:

-- Findings in fertility in CAH patients on Modified-Release Hydrocortisone Capsules (MR-HC, Efmody (R) ).

   --      Findings on control of CAH on MR-HC. 
   --      The burden of illness associated with adolescent and adult CAH. 
   --      Literature review on supraphysiological g lucocorticoid dosing in CAH. 
   --      MR-HC effects on mineralocorticoid requirements. 

CAH occurs when the production of cortisol from the adrenal gland is limited due to a genetic deficiency. CAH is associated with over-production of male sex hormones resulting in ambiguous genitalia at birth, precocious sexual development, infertility in men and women, and increased mortality through adrenal crisis.

Around 450,000 people globally are estimated to be living with a CAH disorder yet there is no standard treatment. Instead, a variety of steroids are used but data shows around two thirds of people living with CAH still have problems with disease control[i].

" Diurnal is committed to supporting research into diseases of cortisol deficiency, and developing solutions to support patients with these life-long disorders," said Richard Bungay, Interim Chief Executive Officer of Diurnal. " The ECE meeting marks a significant opportunity to contribute to the discussion by the medical community of recent research and developments in an area which has historically had very few advances. The Diurnal team is excited to be part of this event as we continue to focus on progress in the treatment and management of diseases of cortisol deficiency."

 
 For further information, please visit www.diurnal.co.uk or 
  contact: 
 
                                                    [phone] 
 Diurnal Group plc                                   1000 
 Richard Bungay, Interim Chief Executive Officer 
 
 Panmure Gordon (UK) Limited (Nominated Adviser     [phone] 
  and Joint Corporate Broker)                        2500 
 Corporate Finance: Freddy Crossley, Emma Earl 
 Corporate Broking: Rupert Dearden 
 Stifel Nicolaus Europe Limited (Joint Corporate    [phone] 
  Broker)                                            7600 
 Healthcare Investment Banking: Nicholas Moore, 
  Samira Essebiyea, William Palmer-Brown 
 Corporate Broking: Nick Adams, Nick Harland 
 
                                                    [phone] 
 FTI Consulting (Media and Investor Relations)       1000 
 Simon Conway 
 Victoria Foster Mitchell 
 Alex Davis 
 
                                                    [phone] 
 Vane Percy & Roberts (Medical Communications)       1890 
 Simon Vane Percy 
 

Notes to Editors

About Diurnal Group plc

Diurnal Group plc is a European, UK-headquartered, specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

For further information about Diurnal, please visit www.diurnal.com

[i] Mallappa, A., Merke, D.P. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol 18, 337-352 (2022). https://doi.org/10.1038/s41574-022-00655-w

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAKZGZKMZLGZZZ

(END) Dow Jones Newswires

May 23, 2022 02:01 ET (06:01 GMT)